pdufa.bio
CalendarReadoutsDevicesDecisionsApprovals/yrTrial oddsLearnResearchMethodologyCoveragePricing
Home › PDUFA Calendar › TAK

TAK PDUFA Date: Rusfertide

FDA decision (PDUFA) target 2026-12-31 · Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) · Polycythemia vera
More Cancer & Oncology FDA decisions →All December 2026 PDUFA dates →

The story

Rusfertide is under FDA review to treat share of) · Polycythemia vera.
Full PDUFA calendar ->Every upcoming FDA decision date, by monthLNTH-lnth-2501 . 2026-06-29Same area: Oncology . LNTH-2501 (Gallium-68 edotreotide)AZN-truqap . 2026-06-30Same area: Oncology . TruqapEXEL . 2026-12-03Same month decision . XL092 with atezolizumab
Plain-English summary compiled by pdufa.bio from public FDA, SEC and company sources. Informational only - not investment advice.

TAK run-up into the PDUFA (last ~120 days)

$18.8$15.03
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-12-31
Drug / candidateRusfertide
IndicationPolycythemia vera
CompanyTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)
Market-cap tierMid
Cohort decision-day move (history)±2% median
ClinicalTrials.govNCT05210790 · Breakthrough Therapy Designation (BTD), Fast Track Designation (FTD), Orphan Drug Designation (ODD)

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the TAK PDUFA date?
The FDA PDUFA target date for TAK (Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)) is 2026-12-31 for Rusfertide. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is TAK's drug Rusfertide?
Rusfertide is Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)'s candidate under FDA review for Polycythemia vera.
What typically happens to a mid-cap stock into a PDUFA date?
Historically, mid-cap names had a median decision-day move around ±2% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.